Cargando…
Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer
Preclinical evaluation of therapeutic agents against metastatic breast cancer require cell lines and animal models that recapitulate clinical metastatic breast cancer as much as possible. We have previously used cell lines derived from the neu-N transgenic model to investigate anti-neu targeting of...
Autores principales: | Park, Sunju, Nedrow, Jessie R., Josefsson, Anders, Sgouros, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620237/ https://www.ncbi.nlm.nih.gov/pubmed/28978097 http://dx.doi.org/10.18632/oncotarget.19174 |
Ejemplares similares
-
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
por: Ladjemi, Maha Z, et al.
Publicado: (2011) -
The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009) -
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
por: Nedrow, Jessie R., et al.
Publicado: (2017) -
Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
por: dos Santos, Giovana Tavares, et al.
Publicado: (2017) -
The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)